0001185185-26-001385
SEC filingFY2025 marked a period of deep financial transition: revenue declined 11.4% to $38.7K while net income turned positive at $498.7K — driven entirely by non-operational gains — against a backdrop of persistent negative operating cash flow and management’s explicit acknowledgment that the company has not generated sufficient revenue from operations to support its operations.
Mitesco’s FY2025 revenue of $38.7K reflects the full operational impact of its strategic exit from healthcare clinics — a decision made in Q4 FY2022 due to lack of profitability. With no clinic operations remaining, revenue now stems solely from early-stage Centcore data center services, including remote backup, application hosting, and digital marketing support for internal Robo Agent development. The 11.4% decline from $43.7K in FY2024 confirms the business remains pre-revenue at scale, lacking a commercial customer base or material pipeline.
Net income swung to $498.7K from a $2.5M loss — a 119.9% year-over-year improvement. However, this gain is entirely non-operational in nature and does not reflect progress in core revenue generation or margin expansion. As confirmed by the authoritative financial packet, the improvement arises from gains outside the operating cash flow stream, underscoring a critical disconnect between accounting profit and underlying business viability.
Net cash used in operating activities totaled -$701.6K, worsening from -$514.4K in FY2024. This continued negative operating cash flow occurs despite management’s stated efforts to reduce costs — including relocating domicile from Delaware to Nevada in October 2023. Critically, management affirms: ‘To date, we have not generated sufficient revenue from operations to support our operations’ and ‘We remain undercapitalized.’ These statements are not speculative; they are direct, unambiguous disclosures anchoring the company’s liquidity reality. Without resolution of outstanding obligations, management judges it unlikely the company can attract sufficient capital on reasonable terms — a sobering constraint on execution of its stated growth strategy.